Co-regulation and function of FOXM1/RHNO1 bidirectional genes in cancer

  1. Carter J Barger
  2. Linda Chee
  3. Mustafa Albahrani
  4. Catalina Munoz-Trujillo
  5. Lidia Boghean
  6. Connor Branick
  7. Kunle Odunsi
  8. Ronny Drapkin
  9. Lee Zou
  10. Adam R Karpf  Is a corresponding author
  1. University of Nebraska Medical Cancer, United States
  2. University of Nebraska Medical Center, United States
  3. Roswell Park Comprehensive Cancer Center, United States
  4. University of Pennsylvania Perelman School of Medicine, United States
  5. Massachusetts General Hospital Cancer Center, Harvard Medical School, United States
  6. University of Nebraska Medical Center;, United States

Abstract

The FOXM1 transcription factor is an oncoprotein and a top biomarker of poor prognosis in human cancer. Overexpression and activation of FOXM1 is frequent in high-grade serous carcinoma (HGSC), the most common and lethal form of human ovarian cancer, and is linked to copy number gains at chromosome 12p13.33. We show that FOXM1 is co-amplified and co-expressed with RHNO1, a gene involved in the ATR-Chk1 signaling pathway that functions in the DNA replication stress (RS) response. We demonstrate that FOXM1 and RHNO1 are head-to-head (i.e. bidirectional) genes (BDG) regulated by a bidirectional promoter (BDP) (named F/R-BDP). FOXM1 and RHNO1 each promote oncogenic phenotypes in HGSC cells, including clonogenic growth, DNA homologous recombination repair (HR), and poly-ADP ribosylase (PARP) inhibitor resistance. FOXM1 and RHNO1 are one of the first examples of oncogenic BDG, and therapeutic targeting of FOXM1/RHNO1 BDG is a potential therapeutic approach for ovarian and other cancers.

Data availability

All data generated are found within the manuscript and supporting files. sc-RNA-seq data is deposited in GEO.

The following previously published data sets were used
    1. Ann-Marie Patch 1
    2. Elizabeth L Christie 2
    3. Dariush Etemadmoghadam 3
    4. Dale W Garsed 2
    5. Joshy George 4
    6. Sian Fereday 2
    7. Katia Nones 1
    8. Prue Cowin 2
    9. Kathryn Alsop 2
    10. Peter J Bailey 5
    11. Karin S Kassahn 6
    12. Felicity Newell 7
    13. Michael C J Quinn 1
    14. Stephen Kazakoff 1
    15. Kelly Quek 7
    16. Charlotte Wilhelm-Benartzi 8
    17. Ed Curry 8
    18. Huei San Leong 2
    19. Australian Ovarian Cancer Study Group; Anne Hamilton 9
    20. Linda Mileshkin 10
    21. George Au-Yeung 2
    22. Catherine Kennedy 11
    23. Jillian Hung 11
    24. Yoke-Eng Chiew 11
    25. Paul Harnett 12
    26. Michael Friedlander 13
    27. Michael Quinn 14
    28. Jan Pyman 14
    29. Stephen Cordner 15
    30. Patricia O'Brien 15
    31. Jodie Leditschke 15
    32. Greg Young 15
    33. Kate Strachan 15
    34. Paul Waring 16
    35. Walid Azar 2
    36. Chris Mitchell 2
    37. Nadia Traficante 2
    38. Joy Hendley 2
    39. Heather Thorne 2
    40. Mark Shackleton 10
    41. David K Miller 7
    42. Gisela Mir Arnau 2
    43. Richard W Tothill 10
    44. Timothy P Holloway 2
    45. Timothy Semple 2
    46. Ivon Harliwong 7
    47. Craig Nourse 7
    48. Ehsan Nourbakhsh 7
    49. Suzanne Manning 7
    50. Senel Idrisoglu 7
    51. Timothy J C Bruxner 7
    52. Angelika N Christ 7
    53. Barsha Poudel 7
    54. Oliver Holmes 1
    55. Matthew Anderson 7
    56. Conrad Leonard 1
    57. Andrew Lonie 17
    58. Nathan Hall 18
    59. Scott Wood 1
    60. Darrin F Taylor 7
    61. Qinying Xu 1
    62. J Lynn Fink 7
    63. Nick Waddell 7
    64. Ronny Drapkin 19
    65. Euan Stronach 8
    66. Hani Gabra 8
    67. Robert Brown 8
    68. Andrea Jewell 20
    69. Shivashankar H Nagaraj 7
    70. Emma Markham 7
    71. Peter J Wilson 7
    72. Jason Ellul 2
    73. Orla McNally 11
    74. Maria A Doyle 2
    75. Ravikiran Vedururu 2
    76. Collin Stewart 21
    77. Ernst Lengyel 20
    78. John V Pearson 1
    79. Nicola Waddell 1
    80. Anna deFazio 11
    81. Sean M Grimmond 5
    82. David D L Bowtell
    (2015) HGSC RNA-seq
    EGAD00001000877.

Article and author information

Author details

  1. Carter J Barger

    Eppley Institute, University of Nebraska Medical Cancer, Omaha, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Linda Chee

    Eppley Institute, University of Nebraska Medical Center, Omaha, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Mustafa Albahrani

    Eppley Institute, University of Nebraska Medical Center, Omaha, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Catalina Munoz-Trujillo

    Eppley Institute, University of Nebraska Medical Center, Omaha, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Lidia Boghean

    Eppley Institute, University of Nebraska Medical Center, Omaha, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Connor Branick

    Eppley Institute, University of Nebraska Medical Center, Omaha, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Kunle Odunsi

    Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Ronny Drapkin

    University of Pennsylvania Perelman School of Medicine, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Lee Zou

    Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Adam R Karpf

    Eppley Institute, University of Nebraska Medical Center;, Omaha, United States
    For correspondence
    adam.karpf@unmc.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0866-0666

Funding

National Institutes of Health (P30CA036727)

  • Adam R Karpf

Rivkin Center for Ovarian Cancer

  • Adam R Karpf

Fred & Pamela Pamela Buffett Cancer Center

  • Adam R Karpf

UNMC Fellowship

  • Carter J Barger

McKinsey Ovarian Cancer Research Fund

  • Adam R Karpf

UNMC Core Facility Users Grant

  • Adam R Karpf

National Institutes of Health (T32CA009476)

  • Carter J Barger

National Institutes of Health (F99CA212470)

  • Carter J Barger

National Institutes of Health (P50CA228991)

  • Ronny Drapkin

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2021, Barger et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,456
    views
  • 340
    downloads
  • 21
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Carter J Barger
  2. Linda Chee
  3. Mustafa Albahrani
  4. Catalina Munoz-Trujillo
  5. Lidia Boghean
  6. Connor Branick
  7. Kunle Odunsi
  8. Ronny Drapkin
  9. Lee Zou
  10. Adam R Karpf
(2021)
Co-regulation and function of FOXM1/RHNO1 bidirectional genes in cancer
eLife 10:e55070.
https://doi.org/10.7554/eLife.55070

Share this article

https://doi.org/10.7554/eLife.55070

Further reading

    1. Cancer Biology
    2. Immunology and Inflammation
    Simei Go, Constantinos Demetriou ... Eric O Neill
    Research Article

    The immunosuppressive microenvironment in pancreatic ductal adenocarcinoma (PDAC) prevents tumor control and strategies to restore anti-cancer immunity (i.e. by increasing CD8 T-cell activity) have had limited success. Here, we demonstrate how inducing localized physical damage using ionizing radiation (IR) unmasks the benefit of immunotherapy by increasing tissue-resident natural killer (trNK) cells that support CD8 T activity. Our data confirms that targeting mouse orthotopic PDAC tumors with IR together with CCR5 inhibition and PD1 blockade reduces E-cadherin positive tumor cells by recruiting a hypoactive NKG2D-ve NK population, phenotypically reminiscent of trNK cells, that supports CD8 T-cell involvement. We show an equivalent population in human single-cell RNA sequencing (scRNA-seq) PDAC cohorts that represents immunomodulatory trNK cells that could similarly support CD8 T-cell levels in a cDC1-dependent manner. Importantly, a trNK signature associates with survival in PDAC and other solid malignancies revealing a potential beneficial role for trNK in improving adaptive anti-tumor responses and supporting CCR5 inhibitor (CCR5i)/αPD1 and IR-induced damage as a novel therapeutic approach.

    1. Cancer Biology
    Hyungtai Sim, Hyun Jung Park ... Murim Choi
    Research Article

    Clonal hematopoiesis of indeterminate potential (CHIP) allows estimation of clonal dynamics and documentation of somatic mutations in the hematopoietic system. Recent studies utilizing large cohorts of the general population and patients have revealed significant associations of CHIP burden with age and disease status, including in cancer and chronic diseases. An increasing number of cancer patients are treated with immune checkpoint inhibitors (ICIs), but the association of ICI response in non-small cell lung cancer (NSCLC) patients with CHIP burden remains to be determined. We collected blood samples from 100 metastatic NSCLC patients before and after ICI for high-depth sequencing of the CHIP panel and 63 samples for blood single-cell RNA sequencing. Whole exome sequencing was performed in an independent replication cohort of 180 patients. The impact of CHIP status on the immunotherapy response was not significant. However, metastatic lung cancer patients showed higher CHIP prevalence (44/100 for patients vs. 5/42 for controls; p = 0.01). In addition, lung squamous cell carcinoma (LUSC) patients showed increased burden of larger clones compared to lung adenocarcinoma (LUAD) patients (8/43 for LUSC vs. 2/50 for LUAD; p = 0.04). Furthermore, single-cell RNA-seq analysis of the matched patients showed significant enrichment of inflammatory pathways mediated by NF-κB in myeloid clusters of the severe CHIP group. Our findings suggest minimal involvement of CHIP mutation and clonal dynamics during immunotherapy but a possible role of CHIP as an indicator of immunologic response in NSCLC patients.